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Abstract
Introduction Radiation exposure at a young age is one of the
strongest risk factors for breast cancer. Germline mutations in
genes involved in the DNA-damage repair pathway (DDRP) may
render women more susceptible to radiation-induced breast
cancer.
Methods We evaluated the contribution of germline mutations
in the DDRP genes BRCA1, BRCA2, CHEK2 and ATM to the
risk of radiation-induced contralateral breast cancer (CBC). The
germline mutation frequency was assessed, in a case-only
study, in women who developed a CBC after they had a first
breast cancer diagnosed before the age of 50 years, and who
were (n = 169) or were not (n = 78) treated with radiotherapy
for their first breast tumour.
Results We identified 27 BRCA1, 5 BRCA2, 15 CHEK2 and
4 truncating ATM germline mutation carriers among all CBC
patients tested (21%). The mutation frequency was 24.3%
among CBC patients with a history of radiotherapy, and 12.8%
among patients not irradiated for the first breast tumour (odds
ratio 2.18 (95% confidence interval 1.03 to 4.62); p = 0.043).
The association between DDRP germline mutation carriers and
risk of radiation-induced CBC seemed to be strongest in women
who developed their second primary breast tumour at least 5
years after radiotherapy. Those patients had an odds ratio of
2.51 (95% confidence interval 1.03 to 6.10; p = 0.049) of
developing radiation-induced breast cancer, in comparison with
non-carriers.
Conclusion This study shows that carriers of germline
mutations in a DDRP gene have an increased risk of developing
(contralateral) breast cancer after radiotherapy; that is, over and
above the risk associated with their carrier status. The increased
risk indicates that knowledge of germline status of these DDRP
genes at the time of breast cancer diagnosis may have important
implications for the choice of treatment.
Introduction
Several risk factors for the development of breast cancer, such
as family history, reproductive factors and exposure to radia-
tion, have been identified. Out of all breast cancers, 5 to 10%
can be attributed to germline mutations in familial high-risk
genes such as BRCA1 or BRCA2 that result in a lifetime
breast cancer risk of about 45 to 65% [1]. The penetrance var-
ies between families, depending on 'risk modifiers' such as
hormonal factors, mutation type and also exposure to radiation
[2-4]. Mutations in low-penetrance genes may account for a
larger proportion (10 to 30%) of all breast cancers [5]. The
contribution of these genes might be explained by their role in
the DNA-damage control pathway. For instance, ATM hetero-
zygous carriers have a relative risk of breast cancer of 2.2
compared with the general population and a relative risk of 4.9
for those younger than 50 years of age [6,7]. It has been
shown that particular alterations in the ATM gene are associ-
ated with increased in vitro chromosomal sensitivity toPage 1 of 9
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(CHEK2*1100delC) has been implicated in a twofold
increased risk of breast cancer, functioning as a low-pene-
trance breast cancer susceptibility allele [11-15]. Mutation fre-
quencies reported in the literature indicate that about 10% of
all women with breast cancer diagnosed before the age of 50
years have a germline mutation in BRCA1, BRCA2, ATM or
CHEK2 [1,6,15].
Exposure to ionising radiation is a strong risk factor for breast
cancer. A pooled analysis of eight cohorts by Preston and col-
leagues showed that the increased risk is directly proportional
to the radiation dose received and inversely related to age at
irradiation [16]. For women exposed at the age of 25 years the
excess relative risk per Gy was estimated to be 1.8. Radiation-
induced DNA damage initiates a complex series of overlap-
ping responses responsible for the maintenance of genome
integrity. The increased incidence of breast cancer after expo-
sure to ionising radiation might be restricted to a genetically
defined radiosensitive subpopulation [17]. Candidate genes
(for example BRCA1, BRCA2, CHEK2, ATM, MDM2 and
TP53) are implicated in the maintenance of genome integrity;
their involvement in breast cancer susceptibility and their role
in DNA-damage repair signalling make them excellent candi-
dates as genes with a role in radiation-induced breast cancer
[18].
The use of diagnostic X-rays has not been associated with
increased risk of breast cancer in the general population, with
the exception of frequent chest fluoroscopies in tuberculosis
[19,20]. However, low-dose ionising radiation has recently
been shown to increase the risk of breast cancer significantly
among BRCA1 and BRCA2 mutation carriers [4]. In a retro-
spective cohort study of 1,601 female BRCA1 and BRCA2
mutation carriers we found an association with reported chest
X-ray exposure and significantly increased risk of breast can-
cer (hazard ratio 1.54). Furthermore, a recent publication also
showed a strong association (odds ratio (OR) 3.21) between
CHEK2*1100delC carrier status, breast cancer risk and a his-
tory of chest X-rays [21].
Women with breast cancer in general have a threefold to four-
fold increased risk of developing a new primary cancer in the
opposite breast [22]. The increased risk may be explained by
the same genetic and hormonal factors that caused the first
breast cancer. In addition, radiotherapy for primary breast can-
cer may also contribute to the development of cancer in the
contralateral breast. The contralateral breast can receive a
dose of several Gy of leakage and scattered radiation during
radiation treatment (RT) [23,24]. Several studies have shown
that exposure of the contralateral breast to RT increases the
risk of developing second primary breast cancer among young
women [23,25].
To evaluate the association between germline mutations in
DNA-damage repair pathway (DDRP) genes (BRCA1,
BRCA2, CHEK2 and ATM) and radiation-induced contralat-
eral breast cancer (CBC), we conducted a case-only study.
We assessed the germline mutation frequency in women who
developed CBC, according to their history of RT for the first
breast cancer, and assessed whether DDRP mutation carriers
have an increased risk of radiation-associated breast cancer
compared with that for non-carriers.
Methods
Patients
We examined the interaction of germline mutation status and
exposure to radiotherapy in the pathogenesis of CBC in a
case-only design. Such an approach is especially suitable for
the evaluation of gene-environment interactions [26,27]. The
consecutive breast cancer patients included in this study were
all selected from the hospital tumour registries of The Nether-
lands Cancer Institute (NKI-AVL), Amsterdam, and the Dr Dan-
iel den Hoed Cancer Centre/Erasmus Medical Center
(DDHK), Rotterdam. We achieved an 80% response rate from
all patients who were invited to participate. CBC patients (with
a histologically confirmed second primary breast tumour) were
included if their first breast cancer was diagnosed before the
age of 50 years (between 1966 and 2000) and the second
breast cancer was diagnosed at least 1 year later (n = 247).
One hundred and sixty-nine patients had received radiother-
apy for their primary invasive breast tumour and 78 had not
(main indications for radiotherapy were lymph-node status and
prognosis at the time of diagnosis). All patients had been
treated with surgery, 23% had had chemotherapy in addition
to RT, and 9% had received chemotherapy in the no-RT group
(see also Table 1). Patients who were treated with radiother-
apy received one or more radiation fields with either kilovolt or
megavolt radiation quality. The dose to the ipsilateral primary
tumour site varied from 30.5 Gy (internal mammary chain irra-
diation) to 76 Gy (breast-conserving treatment with a boost
dose). The contralateral breast received about 1 to 10% from
scatter and collimator leakage (this problem continues despite
modern radiation methods). The maximum radiation dose at
the contralateral breast and the dose at the site of the contral-
ateral tumour were estimated from the treatment charts by a
radiation oncologist (NS Russell; details of the calculation of
the radiation dose to the contralateral breast (taking into
account all given doses, fields, machine types, scatter and col-
limator leakage) are available from the authors on request).
Detailed treatment data, disease characteristics and patient
characteristics were obtained from medical records and risk
factor questionnaires (Table 1). Patients were asked to donate
a 20-ml blood sample or permission for the use of paraffin-
embedded tissue blocks, and all patients gave written
informed consent for mutation analysis. This study receivedPage 2 of 9
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Genomic DNA isolation
Genomic DNA was either isolated from peripheral blood lym-
phocytes with the use of DNAzol (Invitrogen, Breda, The Neth-
erlands) methods in accordance with the manufacturer's
instructions, or from three 10-μm paraffin normal tissue slides
in accordance with standard protocols [28]. For histopatho-
logical examination of the tumour we used a haematoxylin/
eosin-stained slide.
Mutation analysis
The complete ATM open reading frame was analysed; each
exon (exons 4 to 65) and corresponding splice sites were
screened for germline mutations by denaturing gradient gel
electrophoresis, identifying 80 to 90% of all ATM mutations
and polymorphisms [29]. Detection of the CHEK2*1100delC
mutation was performed by using denaturing gradient gel elec-
trophoresis. All primers were designed with the Ingeny melt
analysis software; and primer sequences are available from the
authors on request. The products were analysed on a polyacr-
ylamide/20 to 55% urea/formamide gradient gel and run over-
night at 120 V and 59°C.
Using DSDI (detection of small deletions and insertions; gen-
otype analysis on an ABI Prism 3700 DNA analyzer and corre-
sponding software) and allelic discrimination (AD; with
Taqman probes using a ABI Prism 7700 sequence detector)
we screened for BRCA1 and BRCA2 mutations. We chose
the fragments for DSDI and the ADs as those in which we
were able to detect the most frequently occurring known path-
ogenic mutations, including Dutch founder mutations, on the
basis of data from BRCA1/2 screening in breast cancer fami-
lies and in young breast cancer patients from almost all clinical
genetic centres in The Netherlands. In total we screened for
32 different mutations in BRCA1 and 16 in BRCA2, which
represented at the time of analysis about 81% and about 39%
of known mutations occurring in Dutch breast cancer families.
Methods are available from the authors on request.
All aberrations were confirmed by genomic sequence analysis.
Sequence analysis was performed with the ABI PRISM Big-
DyeTerminator Cycle Sequencing Ready Reaction Kit, Version
3.1 (Applied Biosystems, Nieuwerkerk a/d Ijssel, The Nether-
lands). Sequencing products were analysed with the ABI
Prism 3700 DNA analyser and corresponding software.
Statistical analysis
Statistical analyses were performed by using standard meth-
ods for the analysis of case-control studies [30]. We com-
pared the mutation frequency between CBC cases previously
treated with radiation and those not treated with radiation.
ORs and 95% confidence intervals (CIs) were calculated to
evaluate the association between radiation exposure, mutation
carrier status and breast cancer risk. Logistic regression was
performed to examine the effect of potential confounders (age
at first breast cancer, tumour size, lymph node status and fam-
ily history) on risk estimates. Under the assumption that there
is independence between genotype and RT, the OR estimates
the relative risk of CBC associated with radiation among gene
carriers compared with the relative risk of CBC associated
with radiation among non-carriers. All analyses were per-
formed with SPSS 12.0 (SPSS Inc., Chicago, IL, USA).
Table 1
Tumour and patient characteristics, by DDRP mutation carrier status and previous RT exposure
Characteristic Mutation positive (n = 51) Mutation negative (n = 196)
Previous RT No previous RT Previous RT No previous RT
Age at first BC, years 40.3 42.4 41.4 42.3
Age at second BC, years 48.1 51.8 51.1 54.2
Chemotherapy, n (percentage) 11 (27) 1 (10) 28 (22) 5 (7)
Tumour size, cm 1.8 2.9 2.2 2.3
Lymph node positive, n (percentage) 12 (29) 1 (10) 41 (32) 4 (6)
RT dosea, Gy
Mean (range) 1.49 (0.27–3.73) 1.55 (0.24–5.61)
Median 1.32 1.40
Third quartile 1.79 1.89
DDRP, DNA-damage repair pathway; BC, breast cancer; RT, radiation treatment. aRadiation dose to the site of the breast where the tumour had 
developed.Page 3 of 9
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Pathogenic and missense mutation frequencies
For all CBC patients we obtained germline mutation data for
the DDRP genes BRCA1, BRCA2, CHEK2 and ATM. In total,
we identified 51 pathogenic germline mutations in these
DDRP genes among the 247 CBC patients (21%), an
increase over the estimated 10% mutation carriers among all
women with primary breast cancer diagnosed before the age
of 50 years (estimated from mutation frequencies reported
previously [1,6,15]; Table 2). We did not detect multiple path-
ogenic mutations in single patients. We compared the muta-
tion frequency between CBC cases previously treated with
radiation and those not treated with radiation. Among women
who had received radiotherapy for their first breast cancer (n
= 169), we identified 24.3% mutation carriers, in contrast with
only 12.8% among those who had not received radiotherapy
(n = 78). Our data show that women with a pathogenic muta-
tion in one of the tested genes have a 2.18-fold increased risk
(95% CI 1.03 to 4.62) of developing CBC after radiotherapy
for the first breast cancer, compared with women without a
pathogenic mutation. The pattern of a higher proportion of car-
riers among the CBC cases with previous RT than among
those with no previous RT was also found for each of the indi-
vidual genes, although these results did not reach
significance.
The mean age at diagnosis of the first primary breast cancer
was 41 years in the CBC group with previous RT and 42 years
for CBC patients not treated with radiation (Table 1). Further-
more, the mean age at diagnosis of the first primary breast
cancer was 41 years in the mutation carrier group (interquar-
tile range 36 to 47 years) and 42 years in the non-carriers
(interquartile range 38 to 47 years), resulting in the same mean
(and median) age at time of treatment in both groups. Adjust-
ment for age in logistic regression analysis did not materially
affect the risk estimates: the adjusted OR was 2.14 (95% CI
1.01 to 4.55). DDRP mutation carriers had clinico-pathologi-
cal features that were similar to those of 'sporadic' cases.
Tumour size, lymph node status and type of tumour were com-
parable in the mutation-positive and mutation-negative groups
(Table 1). Adjustment for each of these three factors in logistic
regression analysis did not materially affect the risk estimates
for mutation status.
Table 2
Frequencies of contralateral breast cancer patients CBC carrying apathogenic DNA-damage repair pathway mutation
Parameter Breast cancer < 50 yearsa 
(percentage)
All CBC patients 
(n = 247)
Previous RT (n = 169) No RT (n = 78) Carriers versus non-carriers
n Percentage n Percentage n Percentage OR for CBC after RT 95% CI p
DDRP mutated ~10 51 21 41 24.3 10 12.8 2.18 1.03–4.62 0.043
CHEK2 1–2 15 6.1 13 7.7 2 2.6 3.17 0.69–14.39
BRCA1 ~4–5 27 11.3 20 11.8 7 9 1.36 0.55–3.37
BRCA2 ~0.5–1 5 2 4 2.4 1 1.3 1.87 0.21–16.98
ATM truncating ~1–2 4 1.6 4 2.4 0 0 - -
1b 1.3 1.87 0.21–16.98
Results for all contralateral breast cancer (CBC) patients, and patients stratified by previous radiation exposure, are presented. Odds ratio (OR) 
and 95% confidence interval (CI) are given for mutation carriers versus non-carriers to develop radiation-associated breast cancer. DDRP, DNA-
damage repair pathway; RT, radiation treatment. aPublished results; bHypothetical assumption of one case.
Table 3
Frequencies of CBC patients carrying pathogenic DNA-damage repair pathway and ATM missense mutations
Parameter All CBC patients 
(n = 247)
Previous RT 
(n = 169)
No RT
 (n = 78)
Carriers versus non-carriers
n Percentage n Percentage n Percentage OR for CBC after RT 95% CI p
DDRP mutated 51 21 41 24.3 10 12.8 2.18 1.03–4.62 0.043
All patients with only a pathogenic DDRP mutation 37 15 29 17.2 8 10.3 1.8 0.79–4.17
Patients with both a pathogenic DDRP and an ATM 
missense mutation
14 5.7 12 7.1 2 2.6 2.90 0.63–13.30
Patients with only an ATM missense mutation 29 11.7 21 12.4 8 10.3 1.24 0.52–2.94
Results for all contralateral breast cancer (CBC) patients, and patients stratified by previous radiation exposure, are presented. Odds ratio (OR) 
and 95% confidence interval (CI) are given for mutation carriers versus non-carriers to develop radiation-associated breast cancer. DDRP, DNA-
damage repair pathway; RT, radiation treatment.Page 4 of 9
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tions we also detected in ATM a large number of presumed
neutral polymorphisms and missense mutations (Table 3).
Forty-three individuals carried at least one ATM missense
mutation, of whom 7 had multiple ATM missense mutations
[31]. Moreover, 14 patients had a pathogenic mutation in one
of the tested DDRP genes in addition to an ATM missense
mutation. Overall, we did not detect a significantly increased
proportion of women with missense mutations among those
who had received RT compared with those who had not (OR
1.24 (95% CI 0.52 to 2.94)). Although these data are also not
statistically significant, there might be an increased risk of
developing radiation-induced breast cancer in those women
carrying a combination of both a pathogenic DDRP and an
ATM missense mutation (OR 2.90 (95% CI 0.63 to 13.30);
Table 3).
The literature [6,41] shows that ATM missense mutation carri-
ers have an increased risk for breast cancer. Because there is
no conclusive evidence for the function of any of these
missense mutations yet, we did not take these missense muta-
tions into account in the subsequent analysis exploring the
effect of RT.
Effects of age at radiation, radiation dose, and induction 
period
Because age at radiation is a major determinant of breast can-
cer risk, we examined whether younger age at irradiation was
associated with a greater radiation effect in carriers. All
women in our study had their first breast tumour diagnosed
before the age of 50 years, but none of them had cancer
before they were 20 years old. We divided the cases by age
at radiation into those exposed below the age of 40 years and
those exposed between 40 and 50 years of age. Although the
results were not significant, they showed that the radiation
effect might be more pronounced in the younger mutation car-
riers at exposure (Table 4).
The contralateral breast received about 1 to 10% of the total
dose from scatter and collimator leakage from the RT machine.
To investigate whether germline pathological mutations most
strongly affect CBC risk in women who had highest levels of
RT (women were received a dose of 30 to 76 Gy), we com-
pared the estimated maximum radiation dose to the
contralateral breast with the estimated radiation dose at the
site of the tumour in the contralateral breast between mutation
carriers and non-carriers. The mean maximum RT dose and
dose at the site of the tumour in the (contralateral) breast were
comparable for those patients carrying a germline mutation
and those without a germline mutation (Table 1). The dose dis-
tribution among carriers and non-carriers was also compara-
ble, with an interquartile range for maximum RT dose of 1.0 to
1.8 Gy among carriers and 0.9 to 1.9 Gy among non-carriers,
and an interquartile range for the dose at the site of the tumour
of 1.3 to 2.2 Gy among carriers and 1.5 to 2.8 Gy among non-
carriers.
The literature suggests that the increased risk of breast cancer
due to radiation is not observed until at least 5 years after
exposure [32,33]. When we subdivided all cases into two
Table 4
Frequencies of CBC patients carrying apathogenic DNA-damage repair pathway mutation
Age (years) All CBC patients Previous RT No RT Carriers versus non-carriers
n Percentage n Percentage n Percentage OR for CBC after RT 95% CI
<40 (n = 91) 22/91 24 19/67 28 3/24 12 2.77 0.74–10.39
40–50 (n = 156) 29/156 18.6 22/102 21.6 7/54 12.9 1.85 0.73–4.65
Results for all contralateral breast cancer (CBC) patients, and patients stratified by previous radiation exposure, are presented, according to age 
at diagnosis of first primary breast cancer (before the age of 40 years or between 40 and 50 years of age). Odds ratio (OR) and 95% confidence 
interval (CI) are given for mutation carriers versus non-carriers to develop radiation-associated breast cancer. RT, radiation treatment.
Table 5
Frequencies of CBC patients carrying apathogenic DNA-damage repair pathway mutation
Interval (years) All CBC patients Previous RT No RT Carriers versus non-carriers
n Percentage n Percentage n Percentage OR for CBC after RT 95% CI p
1–5 (n = 66) 15/66 22.7 12/49 24.5 3/16 18.8 1.41 0.34–5.78
>5 (n = 181) 36/181 19.9 29/120 24.1 7/62 11.3 2.51 1.03–6.10 0.049
All contralateral breast cancer (CBC) patients, and patients stratified by previous radiation exposure are presented, according to interval between 
first and second primary breast cancer (less than 5 and more than 5 years). Odds ratio (OR) and 95% confidence interval (CI) are given for 
mutation carriers versus non-carriers to develop radiation-associated breast cancer. RT, radiation treatment.Page 5 of 9
(page number not for citation purposes)
Breast Cancer Research    Vol 9 No 2    Broeks et al.groups on the basis of the interval between first and second
breast cancer (1 to 5 years and more than 5 years), we did
indeed observe a difference between these groups (Table 5).
The strongest effect was observed in women who developed
a second primary breast tumour at least 5 years after radiother-
apy; of these, 24% carried a germline mutation in one of the
genes tested, in contrast with only 11% in those who did not
receive any RT. Thus, at least 5 years after RT for the first
breast cancer, women carrying a germline mutation in a DDRP
gene had a significantly increased risk (OR 2.51, 95% CI 1.03
to 6.10; p = 0.049) of developing a radiation-associated CBC
compared with women not carrying such a mutation.
Discussion
This study is, to the best of our knowledge, the first to suggest
that women with a germline mutation in a gene involved in
DDRP have an increased risk of developing radiation-associ-
ated CBC, compared with women who are not carrying such
a mutation. We examined the mutation frequency of BRCA1,
BRCA2, CHEK2 and ATM in women who had developed a
second primary breast tumour at least 1 year after a first breast
cancer diagnosed before the age of 50 years, with or without
RT for their first breast cancer. Such a case-only design is par-
ticularly well suited to the assessment of gene-environment
interactions, although the independent effects of the genes
involved or of radiation cannot be determined from these data
[26,27]. ORs from such a design can be interpreted as the risk
of developing radiation-associated disease for carriers com-
pared with non-carriers. We present evidence for an interac-
tion between mutations in the DDRP genes and radiation for
the first breast cancer in the development of CBC.
Women with breast cancer have in general a threefold to four-
fold increased risk of developing a new primary cancer in the
contralateral breast [22]. The 15-year cumulative risk of devel-
oping CBC amounts to 10 to 13% [34-36]. BRCA1 and
BRCA2 mutation carriers have an estimated CBC cumulative
risk of 50 to 60% at the age of 70 years. The highest incidence
is seen in the first 5 years after diagnosis of the primary breast
cancer (12 to 33% per year), in contrast with 0.4 to 1% per
year for breast cancer patients in general [37,38]. In a recent
study, based on a consecutive series of breast cancer patients
under 50 years of age, unselected for family history, we
showed that CHEK2*1100delC carriers have a twofold
increased risk of second breast cancer [39].
In the present study we found that mutation carriers have an
additional excess risk, compared with non-carriers, of develop-
ing CBC during follow-up if they received RT for their first
breast tumour. The increased risk due to RT exposure in carri-
ers was mainly seen from 5 years after RT (Table 5). This is in
accordance with the analysis of Boice and colleagues, who
suggested previously that cancers resulting from an exposure
to radiation would develop within predictable time windows; a
latency period of at least 5 to 10 years was suggested for sec-
ond primaries [32]. Metcalf and colleagues have shown that
RT actually protects against local recurrences and ipsilateral
breast cancer among BRCA1 and BRCA2 carriers [36].
Age at time of exposure is known to be a major determinant of
the risk of breast cancer [40]. Our data also suggest that car-
riers in the younger age group at the time of exposure (less
than 40 years old) showed the highest risk of developing radi-
ation-associated CBC, although the difference from those
above 40 years of age at RT was not significant (Table 4).
Importantly, the mean and median ages at diagnosis of the first
primary breast cancer were the same in the CBC patients with
and without prior RT and in CBC patients with and without a
germline mutation, resulting in the same median age at time of
treatment in both groups (Table 1). Indeed, adjustment for age
at first diagnosis did not affect our risk estimates.
The association between breast cancer risk and low-dose
radiation has been a subject of debate. Recently we showed
that diagnostic ionising radiation exposure from chest X-rays
may be associated with a significantly increased breast cancer
risk among women who carry BRCA1 or BRCA2 pathogenic
germline mutations [4]. Comparable findings were reported
for CHEK2*1100delC carriers by Bernstein and colleagues
[21]. In the present study we included women exposed to
higher doses from therapeutic RT, in whom the contralateral
breast is exposed to about 1 to 10% of the total dose (namely
1 to 6 Gy), increasing the likelihood of detecting a gene-radi-
ation interaction. The average (mean and median) maximum
radiation dose (about 1.5 Gy) and the dose at the site of the
tumour (about 1.8 Gy) measured in this study were found to
be comparable between carriers and non-carriers. According
to Preston and colleagues, the excess relative risk at 1 Gy is
2, implying that mutation carriers may have an excess relative
risk of about 2.5 times this risk [16].
We increased the power of our analysis by investigating the
effect of four breast cancer susceptibility genes together, con-
sidering them as a DNA repair gene group. These genes are
all involved in DNA damage response triggered by damage
induced by ionising radiation. An efficient response to DNA
damage is essential for cellular life. The most detrimental form
of damage is DNA double-strand breaks, which can be
induced by ionising radiation and are lethal to the cell if not
repaired. If repaired incorrectly, as a result of improper func-
tioning of the repair machinery caused by mutations in the
genes implicated, double-strand breaks can lead to carcino-
genesis through translocation, inversions or deletions of
genetic material. Although the relative impact of germline
mutations in the separate genes studied in response to RT is
unknown, all of these genes have been identified as crucial to
the repair of RT-induced double-strand breaks. We therefore
considered it justified to regard these genes together as a
DNA repair gene group in our analyses. Although we screened
for only a subset of all mutations in the four genes, there is noPage 6 of 9
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occurred more often in the non-RT group.
In a case-only study there must be independence between
exposure (RT) and genotype (mutation) [26]. By selecting the
RT-exposed and non-RT-exposed groups of CBC patients we
might have consistently selected for those clinico-pathological
factors determining the use of radiotherapy. If mutation carri-
ers were more likely to receive RT for primary breast cancer,
for example because of the presence of a family history of the
disease, alerting the physician to a potentially more aggressive
course of the disease, selection bias might arise in our case-
only study. However, this was not the case, mutation carriers
did not receive RT more often. Information about a family his-
tory of breast cancer was obtained by a mailed questionnaire
and from medical records. In our study population 53% of the
carriers reported breast cancer in the family (33% with an
affected first-degree relative), in contrast with 40% in the non-
carriers (29% with an affected first-degree relative). From the
data collected from medical records and risk factor question-
naires of all women, we concluded that DDRP mutation carri-
ers had clinico-pathological features (such as size and stage)
similar to those of 'sporadic' cases. Adjustment for each of
these factors in logistic regression analysis did not materially
affect the risk estimates for mutation status. In addition, the
percentages of patients receiving chemotherapy were compa-
rable for mutation carriers and non-carriers. Consequently, the
genetic factors (the genetic status was not known at time of
treatment) under study did not affect treatment choice, justify-
ing our assumption of independence between radiation and a
mutation carrier status, which is needed for a case-only study.
In addition, in a related project studying the effect of BRCA1,
BRCA2 and CHEK2*1100delC germline mutations on sur-
vival and disease outcome in a large cohort of unselected
breast cancer patients (diagnosis before 50 years of age), we
found that the tumour characteristics of CHEK2*1100delC
carriers did not differ significantly from those of non-carriers.
Importantly, in that same study we also found that the propor-
tion of breast cancer patients receiving radiotherapy did not
significantly differ between the CHEK2*1100delC carriers
and non-carriers [39].
Although the effect of pathogenic DDRP gene mutations on
breast cancer risk seems evident, the role of most ATM mis-
sense mutations remains unclear. Generally, the idea is that
there are two groups of ATM heterozygotes in the general
population, each with different cancer risks: those with a wild-
type and a truncating mutation allele and those with a wild-type
and a missense mutation allele. Several epidemiological stud-
ies have shown that relatives of patients with ataxia-tel-
angiectasia heterozygotic for an ATM germline mutation have
an increased risk of breast cancer [6]. Carriers of mutations
predicted to encode a full-length ATM protein had cancer risks
similar to those of people carrying truncating mutations,
predicting that both type of mutation in these families are path-
ogenic for ataxia-telangiectasia as well as for breast cancer
[6,41]. Most studies try to predict the relevance of a particular
mutation on the basis of co-segregation in breast cancer fam-
ilies, the location in a functional domain or interference with the
splicing machinery [42]. Nevertheless, only a few studies have
presented the functional analyses necessary to assess the bio-
logical impact of unidentified variants found frequently in ATM
[43]. We found that ATM missense mutations, those detected
in our study, do not by themselves contribute to an increased
risk of breast cancer after exposure to radiation. Although not
significant, there might be an increased risk of developing
CBC after RT when patients have both a pathogenic DDRP
and an ATM missense mutation (Table 3). This trend suggests
that ATM missense mutations might have a risk-modifying
effect after radiation exposure.
It has been hypothesised that a multigenic model might explain
breast cancer susceptibility in a large part of the population. It
has been shown that, although mutations in certain genes had
marginal or no associations with risk when studied in isolation,
they showed significant association when combined with vari-
ant alleles in other genes [44]. It will be necessary to confirm
the potential pathogenic-missense mutation (gene-gene) inter-
action findings of this study by a larger-scale study designed
specifically to examine the joint effects of radiation exposure
and genetic susceptibility of breast cancer risk (for example
the Women's Environmental Cancer and radiation epidemiol-
ogy ('WECARE') study [45]).
Conclusion
Our data imply that there is a subgroup in the female popula-
tion with increased susceptibility to radiation-induced breast
cancer. The characterisation and identification of such a radi-
osensitive subgroup, if confirmed by others, will have implica-
tions for both diagnostic testing and the need for tailored
treatment strategies. It provides a scientific basis for mutation
analysis and subsequently, following the mutation analysis, an
intensified follow-up protocol for mutation carriers. Identifica-
tion of women susceptible to radiation damage will contribute
to the risk/benefit assessment of radiation therapy versus
alternative therapeutic options (such as breast-conserving sur-
gery plus local radiotherapy or mastectomy).
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